NYSE · OGN
Healthcare · Drug Manufacturers - General
$13.66
Up+$0.02 (+0.11%)
Updated Sep 16, 2026, 11:12 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
OGN closed at $13.66 after 20 trading sessions, down 0.15% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $13.65 | $13.68 | $13.65 | $13.66 | 3.59M |
| Sep 14, 2026 | $13.64 | $13.67 | $13.64 | $13.65 | 1.25M |
| Sep 11, 2026 | $13.65 | $13.65 | $13.63 | $13.64 | 1.73M |
| Sep 10, 2026 | $13.66 | $13.66 | $13.63 | $13.63 | 2.08M |
| Sep 9, 2026 | $13.78 | $13.78 | $13.635 | $13.67 | 5.56M |
| Sep 8, 2026 | $13.77 | $13.78 | $13.75 | $13.75 | 1.63M |
| Sep 4, 2026 | $13.76 | $13.78 | $13.76 | $13.78 | 4.87M |
| Sep 3, 2026 | $13.77 | $13.78 | $13.725 | $13.77 | 3.92M |
| Sep 2, 2026 | $13.77 | $13.78 | $13.76 | $13.77 | 3.63M |
| Sep 1, 2026 | $13.75 | $13.785 | $13.75 | $13.76 | 3.44M |
| Aug 31, 2026 | $13.76 | $13.77 | $13.75 | $13.76 | 4.05M |
| Aug 28, 2026 | $13.76 | $13.77 | $13.76 | $13.76 | 2.71M |
| Aug 27, 2026 | $13.76 | $13.77 | $13.76 | $13.76 | 3.19M |
| Aug 26, 2026 | $13.74 | $13.77 | $13.74 | $13.77 | 4.15M |
| Aug 25, 2026 | $13.74 | $13.76 | $13.74 | $13.75 | 3.56M |
| Aug 24, 2026 | $13.73 | $13.76 | $13.72 | $13.75 | 4.58M |
| Aug 21, 2026 | $13.74 | $13.76 | $13.73 | $13.75 | 1.77M |
| Aug 20, 2026 | $13.70 | $13.74 | $13.70 | $13.74 | 4.05M |
| Aug 19, 2026 | $13.71 | $13.74 | $13.69 | $13.73 | 3.31M |
| Aug 18, 2026 | $13.70 | $13.72 | $13.665 | $13.68 | 2.16M |
The latest Smart Investors Daily articles mentioning OGN.
OGN research
Company profile and research snapshot.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | Neutral | — |
| Apr 28, 2026 | Piper Sandler | Neutral | — |
| Feb 24, 2026 | Barclays | Underweight | — |
| Dec 9, 2025 | Barclays | Underweight | — |
| Nov 11, 2025 | JP Morgan | Underweight | — |
No generated briefing is available yet.
Yahoo · Sep 14, 2026
JERSEY CITY, N.J., September 14, 2026--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.
SeekingAlpha · Sep 12, 2026
Yahoo · Sep 10, 2026
Investors hammered Cooper Companies on Thursday after the medtech's fiscal third-quarter sales lagged Wall Street's expectations.
Yahoo · Sep 2, 2026
VANCOUVER, BC / ACCESS Newswire / September 2, 2026 / . ("Orogen" or the "Company") (TSXV:OGN)(OTCQX:OGNNF) is pleased to announce the acquisition of the Toro de Oro and El Gigante gold projects in Southwest Utah, USA.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OGN.
